This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £27.5 million (before expenses) in aggregate by way of the Placing and Subscription (which were also announced on 8 December 2020), and the Open Offer.
As the Open Offer was oversubscribed, the Directors of the Company will use their discretion to undertake a scaling back process that will have regard to those Qualifying Shareholders who were not offered the opportunity to participate in the Placing.
Application has been made to the London Stock Exchange for the admission of 30,513,341 New Shares to trading on AIM (“Admission”). This comprises (i) 27,373,337 Placing Shares; (ii) 404,440 Subscription Shares; and (iii) 2,735,564 Open Offer Shares. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares. Admission is expected to occur on or around 5 January 2021.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 December 2020.
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £27.5 million (before expenses) in aggregate by way of the Placing and Subscription (which were also announced on 8 December 2020), and the Open Offer.
As the Open Offer was oversubscribed, the Directors of the Company will use their discretion to undertake a scaling back process that will have regard to those Qualifying Shareholders who were not offered the opportunity to participate in the Placing.
Application has been made to the London Stock Exchange for the admission of 30,513,341 New Shares to trading on AIM (“Admission”). This comprises (i) 27,373,337 Placing Shares; (ii) 404,440 Subscription Shares; and (iii) 2,735,564 Open Offer Shares. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares. Admission is expected to occur on or around 5 January 2021.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 December 2020.
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £27.5 million (before expenses) in aggregate by way of the Placing and Subscription (which were also announced on 8 December 2020), and the Open Offer.
As the Open Offer was oversubscribed, the Directors of the Company will use their discretion to undertake a scaling back process that will have regard to those Qualifying Shareholders who were not offered the opportunity to participate in the Placing.
Application has been made to the London Stock Exchange for the admission of 30,513,341 New Shares to trading on AIM (“Admission”). This comprises (i) 27,373,337 Placing Shares; (ii) 404,440 Subscription Shares; and (iii) 2,735,564 Open Offer Shares. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares. Admission is expected to occur on or around 5 January 2021.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 December 2020.
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £27.5 million (before expenses) in aggregate by way of the Placing and Subscription (which were also announced on 8 December 2020), and the Open Offer.
As the Open Offer was oversubscribed, the Directors of the Company will use their discretion to undertake a scaling back process that will have regard to those Qualifying Shareholders who were not offered the opportunity to participate in the Placing.
Application has been made to the London Stock Exchange for the admission of 30,513,341 New Shares to trading on AIM (“Admission”). This comprises (i) 27,373,337 Placing Shares; (ii) 404,440 Subscription Shares; and (iii) 2,735,564 Open Offer Shares. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares. Admission is expected to occur on or around 5 January 2021.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 December 2020.
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
